Trigeminal nerve stimulation: a recently approved treatment approach in attention deficit hyperactivity disorder

Abstract

Attention-deficit hyperactivity disorder (ADHD) with its high prevalence is a growing area of concern and research, whereas exact underlying pathophysiology remains unknown. Behavioral therapy and multiple medications include methylphenidate, atomoxetine, and amphetamines while trigeminal nerve stimulator (TNS) is the first medical device in ADHD with FDA approval. The aim of this article is to evaluate the latest studies in this field.

Newer Neuromodulation Techniques for Psychiatric Disorders: A 2023 Update

“…46 Existing evidence supports the potential role of trigeminal nerve stimulation in managing major depressive disorder, posttraumatic stress disorder, attention-deficit hyperactivity disorder (ADHD) and epilepsy. [44][45][46][47][48]…”